SAN FRANCISCO, Nov. 4, 2016 /PRNewswire/ -- Fluxion Biosciences announced today the release of a second generation of its IonFlux automated patch clamp family of products. IonFlux Mercury will replace and update the existing IonFlux product family. While IonFlux systems were previously distributed by Molecular Devices, the new product line will be sold directly by Fluxion Biosciences and its partners. IonFlux systems are used all over the world in industry and academic laboratories and are leading systems in ligand and voltage gated ion channel screening. Unique in-plate perfusion provides continuous compound flow, allowing for assay simplification and speed, even for otherwise complicated and long assays. With IonFlux Mercury, Fluxion takes the platform to a new level by enhancing all aspects of its operation. The platform adds new features such as remote and touch screen experiment execution, highly extended recording times, new streamlined fluid exchange, standardized temperature control, and integrated current clamp. IonFlux Mercury is the most compact yet full featured stand-alone high throughput automated patch clamp instrument on the market. "We believe that the new updates to the IonFlux system will greatly enhance all aspects of an otherwise well proven and unique automated patch clamp system", explained Dr. Ali Yehia, VP IonFlux Product at Fluxion. The IonFlux Mercury will replace the IonFlux 16 while the IonFlux Mercury HT will replace the IonFlux HT. Both systems will be sold exclusively by Fluxion Biosciences and are available for pre-ordering now. All IonFlux 16 and HT system sold within this year are upgradeable to Mercury. Please contact Fluxion Biosciences for more information. http://firstname.lastname@example.orgAbout Fluxion Biosciences Fluxion Biosciences manufactures the IonFlux™ automated patch clamp system for ion channel drug discovery. The system deploys a unique in-plate cell attachment, recording and drug delivery system that provides rapid parallel recordings for ligand- and voltage-gated channels and facilitates complicated drug screening assays. Premier institutions globally use Fluxion's pioneering platforms, including the IsoFlux liquid biopsy system and the BioFlux cell analysis system in various disease research areas, including cancer, microbiology, and immunology.